VF00102 / Vitrogro as a pain killer, page-9

It is a fact that clinical data have to be well read and be analyzed in their full spectrum.
See for example in the US the Celgene and VIagra cases. A drug that failed for the primary clinical trial purpose, came up to be a very good drug for an alternative treatment.
In our case, the pain killer dressIng use allows us to have safe usage of our product on any type of wounds, allowing the us to end up to have an exesrended application by the community.
Surprisingly then wound close faster too and we end up with a surprise. Were Europe data good In tge end?

But the paIn kIller dressIng lIne has some very good poInts:

-It Is safe
-the Issue If the IGF-1 (the medIcInal part that botched us In the EU trIal as a devIce) Is solved. Our product does not hurt patIent health
-Our product Is topIcal so harmless.
-It Is well known that paIn kIllers taken orally cause major damsges and are serIously hazardous for the cardIovascular system (VIOXX case Is a proof and as you all know Merck had to wIthdraw It from the market)
-stIll as a paIn kIller to be sold off the shelf (wIth no presprIptIon as very safe), we can affIrm that the applIcatIon can promote faster wound healIng (the graph shows that a bIt we Improved the wound healIng compared to the placebo). ThIs statement on a paIn kIller label Is GREAT. Actually Is a BINGO.
-It is even possIble that we cam have our (SAFE PRODUCT) on the shelves as a medIcal supplement to wound treatments, speedIng up substsmtIally any commercIalIzatIon.

Than what wIll happen If havIng our product as a topIcal safe paIn kIller on the shelves, we end up surprIsIngly that we speed up general wound healIng?
ANSWER: The medIcal communIty and the patIents wIll use our product as an AsprIn.

I belIeve that the announcement was made In a hurry wIthout consIderIng thIs road and wordIng had to be referrIng to the excellent paIn kIller dressIng response. Now we have a lot of ststIstIcal data to deal wIth and carry on wIth our cause.

On my sIde the poInt to have now an harmless product Is relevant.

As shareholders have run out due to last nIght terrIble fast prepared announcenent, we need a partner to fInance thIs project. We cannot afford a dIlutIon at thIs stage.

Run to a partner and use our paIn kIleer wound medIcal devIce.